1. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine.
- Author
-
Dimopoulos, Meletios A., Kantarjian, Hagop, Estey, Elihu, O'Brien, Susan, Delasalle, Kay, Keating, Michael J., Freireich, Emil J., Alexanian, Raymond, Dimopoulos, M A, Kantarjian, H, Estey, E, O'Brien, S, Delasalle, K, Keating, M J, Freireich, E J, and Alexanian, R
- Subjects
ADENOSINES ,LEGG-Calve-Perthes disease ,THERAPEUTICS ,CLINICAL trials ,COMPARATIVE studies ,IMMUNOGLOBULINS ,LONGITUDINAL method ,LYMPHOPROLIFERATIVE disorders ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,EVALUATION research ,DISEASE remission - Abstract
Objective: To evaluate the activity of 2-chlorodeoxyadenosine (2CdA) in the treatment of patients with Waldenstrom macroglobulinemia.Design: Uncontrolled phase II trial.Setting: Tertiary, referral cancer center.Patients: Twenty-nine consecutive, symptomatic patients with Waldenstrom macroglobulinemia, of whom 9 were previously untreated.Intervention: 2-Chlorodeoxyadenosine was administered as a continuous intravenous infusion at a dose of 0.1 mg/kg body weight per day for 7 days. Only two courses of 2CdA were given and responding patients were then followed without further treatment.Measurements and Main Results: A total of 17 (59%) patients responded, including all of those who were newly diagnosed and 40% of those who had failed previous therapies. Treatment was well tolerated except for one death in a patient who had presented with severe pancytopenia. With a median follow-up of 7 months, only one responding patient has relapsed.Conclusion: 2-Chlorodeoxyadenosine is a nucleoside analog that was effective in most patients with Waldenstrom macroglobulinemia and was associated with little toxicity. [ABSTRACT FROM AUTHOR]- Published
- 1993
- Full Text
- View/download PDF